Aelis Farma: Publication of the 2021 Annual Financial Report
27 April 2022 - 02:00AM
Business Wire
Regulatory News:
Aelis Farma (ISIN code: FR0014007ZB4 – ticker: AELIS)
(Paris: AELIS), a clinical-stage biopharmaceutical company
specialized in the development of treatments for brain diseases
(the « Company »), announces today that its annual financial
report for the financial year ended December 31, 2021 has been made
available to the public and filled with the French Financial
Markets Authority (Autorité des marchés financiers).
The Company's annual financial report includes:
- the management report; - the report on
corporate governance; - the annual financial statements; - the
statutory auditors’ reports.
It can be consulted on the Company’s website at
www.aelisfarma.com.
***
About AELIS FARMA
Founded in 2013, Aelis Farma is a biopharmaceutical company that
is developing a new class of drugs, the Signaling Specific
inhibitors of the CB1 receptor of the endocannabinoid system
(CB1-SSi). These new molecules hold great potential in the
treatment of many brain diseases. CB1-SSi were developed by Aelis
Farma on the basis of the discovery of a new natural defense
mechanism of the brain made by the team of Dr. Pier Vincenzo
Piazza, CEO of the Company, when he was Director of the Inserm
Magendie Neurocentre in Bordeaux. For these discoveries, Dr. Piazza
was awarded the Grand Prix of Inserm, and the Grand Prix of
Neurology of the French Academy of Sciences, which are among the
most prestigious French awards for medicine and neurology.
Aelis Farma is developing two first-in-class drug candidates
that are at the clinical stage, AEF0117 and AEF0217, and has a
portfolio of innovative CB1-SSi for the treatment of other diseases
associated with dysregulation of CB1 receptor activity.
AEF0117, which targets the disorders due to excessive cannabis
use (addiction and psychosis), has demonstrated efficacy in a phase
2a clinical trial and will enter a phase 2b clinical trial in the
United States in 2022. Aelis Farma has an exclusive option license
agreement with Indivior PLC, a leading pharmaceutical company in
the treatment of addiction, for the development and
commercialization of AEF0117 for disorders due to excessive
cannabis use. As part of this agreement, Aelis Farma received $30
million (option payment). If Indivior exercises the license option
at the end of the phase 2b, Aelis Farma will receive a $100 million
license fee (potentially in 2024) and up to $340 million in
additional payments contingent on the achievement of development,
regulatory and commercial milestones, as well as royalties on net
sales of AEF0117 ranging between 12% and 20%.
AEF0217, which targets various cognitive disorders including
those associated with Down syndrome, is progressing successfully in
its phase 1/2 program and could provide the first proof of efficacy
in early 2023. This compound has undergone an extensive preclinical
proof-of-concept program using highly innovative and highly
predictive tests to assess cognitive functions. In this context,
AEF0217 has demonstrated its ability to completely reverse deficits
in several models of cognitive disorders such as Down syndrome and
Fragile X syndrome, as well as in models of certain cognitive
deficits associated with aging.
Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis
Farma has a team of 24 highly qualified employees and has benefited
from investments from the Nouvelle-Aquitaine Region, Inserm
Transfert Initiative, Bpifrance, regional funds ACI, NACO and
Aqui-invest and IRDI Capital Investissement.
For more information: www.aelisfarma.com
ISIN: FR0014007ZB4 Ticker: AELIS B Compartment
of Euronext Paris
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220426005998/en/
AELIS FARMA Pier Vincenzo Piazza Co-founder and CEO
contact@aelisfarma.com
NewCap Dusan Oresansky/Marine de Fages Investor Relations
aelis@newcap.eu +33 1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
nmerigeau@newcap.fr +33 1 44 71 94 98
Aelis Farma (EU:AELIS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aelis Farma (EU:AELIS)
Historical Stock Chart
From Mar 2023 to Mar 2024